Quantitative liver function imaging and whole genome sequencing - Effective modalities for a new era in personalised decision-making for operable colorectal liver metastases?
Welsh F. et al, (2025), Hpb (oxford), 27, 553 - 561
A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data
Ansari-Pour N. et al, (2024), Blood, 144, 1909 - 1910
Longitudinal Analysis of t(11;14) and t(4;14) Genomes Reveals Distinct Evolutionary Trajectories in Multiple Myeloma
Hudson-Lund B. et al, (2024), Clinical lymphoma myeloma & leukemia, 24, S163 - S164
Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
Gooding S. et al, (2024), Blood, 144, 3333 - 3334
Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones
Ansari-Pour N. et al, (2023), Blood, 142
Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients
Agarwal G. et al, (2023), Blood, 142
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.
Gooding S. et al, (2022), Blood, 140, 1816 - 1821
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.
Sudha P. et al, (2022), Clin cancer res, 28, 2854 - 2864
Loss of COP9 signalosome gene-containing 2q region is associated with lenalidomide and pomalidomide resistance in myeloma patients
Gooding S. et al, (2021), Blood, 138, 458 - 459
Association of MSY haplotype background with nonobstructive azoospermia is AZF-dependent: A case-control study.
Seyedin A. et al, (2021), Andrologia, 53